Clinical Evidence

Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial
Complementary Therapies in Medicine.2017; 33 (2017) 1–5. DOI: 10.1016/j.ctim.2017.05.006
Insulin resistance and type 2 diabetes strongly influence the induction of clustering of interrelated plasma lipid and lipoprotein abnormalities, which include reduced HDL cholesterol, a predominance of small dense LDL particles, and elevated triglyceride levels. Each of these dyslipidemic features is associated with an increased risk of cardiovascular disease. Hence, in the case of diabetic management, blood lipid management is also very crucial to avoid the secondary complications affecting heart and circulatory system. Preclinical reports indicate the potential of curcuminoids to influence both the blood sugar and lipid profile.

To enumerate the effect of curcuminoids on serum lipids in human diabetic subjects.


The study was a 12-week randomized double-blind placebo-controlled trial involving 118 T2D subjects. The dosage involved administration of 1000mg plus 10 mg piperine per day or placebo plus standard care for T2D. Serum concentrations of lipids including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), lipoprotein(a) [Lp(a)], and non-HDL-C were determined at baseline and at the end of the trial.

  • At the end of the study, it was found there were significant reductions in serum levels of TC, non-HDL-C, and Lp(a) compared to the placebo group
  • Elevations in serum HDL-C levels in the curcuminoids group as compared with the placebo group

The study concluded that curcuminoids supplementation can reduce serum levels of atherogenic lipid indices including non-HDL-C and Lp(a). Therefore, curcuminoids supplementation could contribute to a reduced risk of cardiovascular events in dyslipidemic patients with T2D.